Psychotropic medication use by CNS-LS threshold.

<p>*<i>P</i><0.0001 compared with CNS-LS <13; chi-square test. CNS-LS, Center for Neurologic Study–Lability Scale; TCA, tricyclic antidepressant(s). Note: Group with CNS-LS ≥21 is a subset of the group with CNS-LS ≥13.</p

Sample interim PRISM registry report available to activated sites.

<p>CNS-LS, Center for Neurologic Study–Lability Scale; PRISM, PBA Registry Series.</p

Impact of neurological condition on quality of life by CNS-LS threshold.

<p>*<i>P</i><0.0001 compared with CNS-LS <13; two-sample <i>t</i>-test. CNS-LS, Center for Neurologic Study–Lability Scale. Note: Group with CNS-LS ≥21 is a subset of the group with CNS-LS ≥13.</p

PBA symptom prevalence by CNS-LS threshold.

<p>AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CNS-LS, Center for Neurologic Study–Lability Scale; MS, multiple sclerosis; PBA, pseudobulbar affect; PD, Parkinson’s disease; PRISM, PBA Registry Series; TBI, traumatic brain injury.</p

Power Wheelchair Use in Persons with ALS: Changes over Time

<div><p></p><p>Objectives: To survey persons with ALS at 1 month and 6 months after receiving power wheelchairs to determine long term use, comfort and function as well as the power wheelchair impact on daily tasks and quality of life.</p><p>Methods: 33-question survey and Psychosocial Impact of Assistive Devices Scale (PIADS) was sent 1 month after getting a new power wheelchair, follow up survey sent at 6 months.</p><p>Results: Based on satisfaction and feature use survey results, at one month, 81% of users found the power wheelchair overall comfort to he high, 88% found their overall mobility to be improved and 95% found it easy to use. Their quality of life increased and pain decreased at one month and six months. According to the PIADS, the power wheelchair gave users increased ability to participate and sense of competence.</p><p>Conclusions: This study has important results for the ALS community, as it is the first to assess power wheelchair users at one month and six months after power wheelchair procurement. Our results demonstrate the impact the power wheelchair has on mobility, psychosocial issues, functional abilities and quality of life for a person with ALS.</p></div

Published PBA symptom prevalence estimates by primary neurological condition.

<p>Shading indicates multiple estimates. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CNS-LS, Center for Neurologic Study–Lability Scale; MS, multiple sclerosis; PBA, pseudobulbar affect; PD, Parkinson’s disease; PRISM, PBA Registry Series; TBI, traumatic brain injury. ^aPatient interview; ^bCNS-LS ≥13 (higher estimate), CNS-LS ≥21, lower estimate; ^c Poeck criteria: pathological affect could be mood congruent (emotional lability) or incongruent (pathological laughing and crying); ^dRetrospective review of hospital or clinic records; ^eMailed questionnaire; ^fEmotional lability questionnaire (ELQ); ^gAscertainment method unknown; ^hPatient interview, Poeck criteria; ⁱBrief questionnaire (uncontrollable laughing/crying when not happy/sad); ^jCNS-LS ≥13 (highest estimate), CNS-LS ≥17 (middle estimate), Cummings Involuntary Emotional Expression Disorder criteria (lowest estimate); ^kCNS-LS ≥17 (lower estimate), CNS-LS ≥13 (higher estimate); ^lPathological Laughing and Crying Scale (PLACS) ≥10 and score of ≥2 on PLACS items 2 (frequency), 13 (loss of voluntary control), and 18 (distress/embarrassment); ^mPatient interview House (lower estimate), and Kim (higher estimate) criteria; ⁿPatient interview House criteria; ^oPatient interview Kim criteria; ^pPatient interview Kim criteria (lower estimate; n = 516) and modified Kim criteria (patient report only without corroboration from relatives; higher estimate); ^qPatient interview Kim criteria at hospital admission (lower estimate) and at 3 months (higher estimate) following stroke.</p

Co-localization of membrane Nogo-A with ozanezumab in skeletal muscle of individual subjects.

<p>A. Triplicate readings are provided from biopsies in Cohort 7 and 8 (single reading from Cohort 5) dose 2 +D22–26, biopsy taken 22–26 days after the second dose; dose 1 +24H, biopsy taken 24 hours after first dose. B. Nogo-A (red), ozanezumab (green) and co-localization (yellow), in muscle biopsy, 24 hours post-dose.</p

Ozanezumab pharmacokinetic parameters.

<p>*Two doses, received 4 weeks apart. AUC_{0–Week 4}, area under the plasma concentration-time curve up to Week 4; AUC_0–∞, area under the plasma concentration-time curve up to infinity; C_max, maximum observed plasma concentration; n, number of subjects; RD, repeated dose; SD, single dose; t_1/2, apparent terminal phase half-life; T_max, time at which C_max was observed. T_max presented as median (range); all other values presented as geometric mean of the log-transformed data (coefficient of variation, CV%).</p

Subject disposition flow diagram for Parts 1 and 2.

<p>N, total number of subjects in group; n, number of subjects in category; PK, pharmacokinetics; SAE, serious adverse events. ^*Two doses, received 4 weeks apart.</p

Subject demographics and baseline characteristics.

<p>*Two doses, received 4 weeks apart.</p>†<p>Remaining patient was of African American/African heritage. ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS functional rating scale-revised; BMI, body mass index; n, number of subjects; STDV, standard deviation; SD, single dose; RD, repeated dose.</p